> vrtx will have plenty of naive trial data that is not tainted by more than one investigational compound<
Not sure I agree here.
If there were a safety problem in a combination trial with VX-950 in the treatment-refractory setting, why do you assume that there would be no taint to affect VX-950 development in the treatment-naïve setting? Even the ~1,000 patients that will have been tested in the treatment-naïve setting are not a lot of patients when it comes to detecting rare side effects.
Market Data 
Markets 
AI
